arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

FATE THERAPEUTICS INC

FATE
$1.85 ▼ -0.25 (-11.69%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
19 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
25
Health
Poor
Bearish
auto_awesome

Analytical Summary

FATE THERAPEUTICS INC faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $219.8M
Dividend Yield —
Revenue Growth -51.2% ↗
Op. Margin None
ROIC -56.3% ↘
FCF / Share $-0.94 ↗
Trailing P/E —
Price / Book 1.0x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

19-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$6.65M
↓ -51.2% —
Net Income Profit after all expenses
$-136.31M
↑ +26.8% —
Operating Margin Operating profit as % of sales
-299.9%
↑ +6.4% —
FCF / Share Free cash flow per share
$-0.94
↑ +13.3% —
Long-Term Debt Long-term obligations
$12.45M
↓ -16.0% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
13
Cash Quality ↓
55

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 19 years · 61 quarters